M1920 Differences in Predictive Factors for Efficacy of Proton Pump Inhibitor (PPI) Therapy for Reflux Esophagitis (RE) and Non-Erosive Reflux Disease (NERD)

2009 ◽  
Vol 136 (5) ◽  
pp. A-446
Author(s):  
Masaki Miyamoto ◽  
Keisuke Takeuchi ◽  
Ken Haruma
Keyword(s):  
Proton Pump Inhibitor ◽  
Proton Pump ◽  
Predictive Factors ◽  
Reflux Esophagitis ◽  
Reflux Disease

scholarly journals The Predictive Factors of Responsiveness to Proton Pump Inhibitor Therapy for Eosinophilic Esophagitis

2019 ◽  
Vol 1 (1) ◽  
pp. 220-230
Author(s):  
Atsushi Hashimoto ◽  
Takashi Sugawa ◽  
Narika Iwakura ◽  
Risa Uemura ◽  
Akinari Sawada ◽  
...  
Keyword(s):  
Multivariate Analysis ◽  
Proton Pump Inhibitor ◽  
Proton Pump ◽  
Predictive Factors ◽  
Eosinophilic Esophagitis ◽  
Reflux Esophagitis ◽  
Odds Ratio ◽  
Proton Pump Inhibitor Therapy ◽  
High Power Field ◽  
Factors Associated

Approximately half of patients with eosinophilic esophagitis (EoE) respond clinically and histologically to proton pump inhibitor (PPI) therapy. Although recent guidelines suggest that PPI-responders and non-responders were included in EoE, it is important to investigate the predictive factors of PPI- responsiveness. This study aimed to determine the rate of PPI- responders and compare the characteristics of PPI-responders and non-responders. Fifty-nine patients with esophageal eosinophilia received PPI therapy for eight weeks, and its efficacy was assessed. PPI- responsiveness was diagnosed based on the relief in symptoms and reduction of intraepithelial eosinophilic infiltration to <15 per high-power field (hpf) after PPI therapy. Multivariate analysis was performed to identify factors associated with PPI-responders. Of the 59 patients, 41 (69.5%) were diagnosed with PPI-responders. The rate of gastrointestinal (GI) screening in the indications for endoscopy was significantly higher in patients with PPI- responders than in those with non-responders. On multivariate analysis, GI screening and presence of reflux esophagitis was associated with an increased odds ratio (OR) of PPI-responders, but presence of rings with a decreased OR of PPI-responders. Presence of reflux esophagitis and absence of rings on endoscopy especially during GI screening might be significant predictive factors for PPI response in patients with EoE.

M1927 Investigation On Daily Onset of Proton Pump Inhibitor On Reflux Esophagitis and Non-Erosive Reflux Disease

2009 ◽  
Vol 136 (5) ◽  
pp. A-447
Author(s):  
Hiroshi Shida ◽  
Yuzo Sakai ◽  
Hiroyuki Hamada ◽  
Tetsuo Takayama
Keyword(s):  
Proton Pump Inhibitor ◽  
Proton Pump ◽  
Reflux Esophagitis ◽  
Reflux Disease

Use of vonoprazan, a novel potassium-competitive acid blocker, for the treatment of proton pump inhibitor-refractory reflux esophagitis in patients with systemic sclerosis

2021 ◽  
pp. 239719832110217
Author(s):  
Yuichiro Shirai ◽  
Noriyuki Kawami ◽  
Katsuhiko Iwakiri ◽  
Masataka Kuwana
Keyword(s):  
Systemic Sclerosis ◽  
Gastroesophageal Reflux Disease ◽  
Proton Pump Inhibitor ◽  
Gastroesophageal Reflux ◽  
Proton Pump ◽  
Reflux Esophagitis ◽  
Reflux Disease ◽  
Acid Reflux ◽  
Mucosal Healing ◽  
Frequency Scale

Proton pump inhibitor-refractory reflux esophagitis is one of the intractable conditions of systemic sclerosis for which new treatments are required. Vonoprazan is a novel potassium-competitive acid blocker and has been shown to have several advantages over conventional proton pump inhibitors, including a long duration of gastric acid suppression. To investigate the efficacy of vonoprazan for treating proton pump inhibitor-refractory reflux esophagitis in patients with systemic sclerosis, 10 patients with proton pump inhibitor-refractory reflux esophagitis who were switched to vonoprazan were selected from our systemic sclerosis database. Reflux esophagitis was evaluated by endoscopy, and gastroesophageal reflux disease–related symptoms were assessed by the frequency scale for the symptoms of gastroesophageal reflux disease questionnaire before and after switching from proton pump inhibitor to vonoprazan at an average interval of 3.5 [2–5.5] months. After switching patients to vonoprazan, the endoscopic findings of reflux esophagitis were significantly improved ( p = .033), and six patients (60%) achieved mucosal healing. The total frequency scale for the symptoms of gastroesophageal reflux disease score was also significantly decreased ( p = .043), mainly by improving the acid reflux score. Vonoprazan was well tolerated and was continued for 15.5 [11.25–23.75] months in all patients. Vonoprazan is a potential treatment option for treating proton pump inhibitor-refractory reflux esophagitis in systemic sclerosis patients.

Potential reasons for proton pump inhibitor failure in the treatment of gastroesophageal reflux disease

2008 ◽  
Vol 149 (40) ◽  
pp. 1881-1888 ◽  
Author(s):  
Márk Juhász ◽  
Zsolt Tulassay
Keyword(s):  
Gastroesophageal Reflux Disease ◽  
Proton Pump Inhibitor ◽  
Gastroesophageal Reflux ◽  
Proton Pump ◽  
Reflux Disease

A protonpumpagátlók (protonpumpa-inhibitorok, PPI) bevezetése új fejezetet nyitott a gastrooesophagealis refluxbetegség (gastroesophageal reflux disease, GERD) kezelésében. A betegek kisebb, de nem jelentéktelen hányadában azonban a PPI sem hatékony. Ilyen esetekben az első kérdés mindig az, hogy a tünetek valóban GERD-nek tulajdoníthatók-e, vagy egyéb betegség után kell kutatnunk. Ha a GERD a legvalószínűbb lehetőség, akkor a további vizsgálatok és a több támadáspontú kezelés előtt fel kell térképeznünk a beteg együttműködését (compliance). Ha az eredménytelen PPI-kezelés hátterében nem helytelenül kezelt GERD áll, akkor számos egyéb kórkép lehetőségét is fel kell vetnünk. Összefoglaló közleményünkben az elkülönítő diagnosztikai kérdésekről adunk áttekintést.

Sign in / Sign up

Export Citation Format

Share Document